You Are a Puppet - How The Elite is Manipulating the MarketsWelcome back Future Demons
Let me make it very clear. I’m here to help you become a better trader, and make money. I’m not a fan of Wall Street, the Elite, the big asset management companies like BlackRock, Vanguard who own most of the biggest companies in the world.
They are known for manipulating the markets, to bait you in, and take advantage of you. They are ruthless. They have secret collabs with journalists around the world from big mainstream media, who will trick you with clickbait articles. But there is way more..
Also there is a big misconception, that the big American asset management companies only hold Western stocks.
No, my friend. They hold Russian and Chinese stocks as well. They try to disguise it of course via shadow companies and banks.
The Elite in USA, Europe, Russia and China are all "working together", and all have part in the world’s biggest companies and share the same goal. More money and more power.
This is NOT a war between sides - East vs West - as they will portrait it in the mainstream media. They have and will continue to brainwash you to believe in this narrative, while they are making money, and the people are dying in war.
This is in reality a war between up and down. The elite vs the people.
Historically it has always been like that. The church vs the illiterate people. The Kingdom vs the peasents.
And there is no difference this time.
——
Why am I telling you this?
We haven’t seen a bear market in 15 years, which is unheard of. We have been very close many times, but suddenly came COVID, which made the markets blossom again. The small businesses went bankrupt, while the giants made money again.
After some time we saw a decline again. Russia invaded Ukraine, and USA (NATO), didn’t try to stop the war. They rejected any kind of diplomatic negotiations.
Why? Obviously because they knew, that especially a proxy-war is good for the markets. All the weapons US has sold to Ukraine, made the markets recover.
Then again very conveniently Israel had an excuse to use their power against Palestine, which meant more war-money, and again the market managed to recover.
The recent little trick is now the 600,000 polio-vaccines UN will give to the Palestinian kids, who are suffering in Gaza. There is catch though, that many is not aware of.
The polio vaccine is made by a French company Sanofi. It only takes a Google search or 2 to find out, who the biggest investor is: Dodge Cox, owned by Johnson, Wells Fargo, Alphabet (Google), Microsoft and more.
Last but not least, let me also state, that the AI hype lately has been the main reason the markets has increased.
But with this post I just want to make it clear, that the Elite, the Deep State, whatever you want to call them, will do whatever it takes to make money. And they are ruthless.
What to do now?
If you are out of the markets, stay out! If you are in the markets secure profit. We have no idea how high we will go, but there is no doubt imo, that this is a huge bubble, and we will most likely soon go into a Depression like we did 100 years ago in the 1930s.
War has historically always been the last instrument before a crash.
Kind Regards
LaPlaces Demon
PS. I know that some people might disagree with my analysis, which is totally ok. What I have learnt the last 10 years trading is to follow the money. And market psychology is my biggest strength.
Vaccine
Pfizer (PFE): Shocking Downward Spiral - $11 Target In Sight?Pfizer (PFE): NYSE:PFE
At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation for Pfizer. For the downward movement, we need to examine more closely how far it can actually fall, but $11 is our minimum expectation.
The only scenario that would make sense here might be a short position for a possible subordinate Wave (iv) between $36.9 and $41.62. Subsequently, for the overarching Wave ((iii)), we expect another decline to a minimum of $22.64 and, in our opinion, a maximum of $9.56. Entering a long position could be too risky over a longer period. For those looking to trade in the short term, there might be a bottom at $25.61, leading up to the potential target zone for Wave (iv). After that, we expect the downtrend to continue, and personally, we are not positioning ourselves long due to the significant risk.
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic:
Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock.
The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month.
Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility.
Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA.
My price target is $10 by the end of this month.
Looking forward to read your opinion about it.
Target 80Following weekly chart.
- Now covid variant on the way
- Novavax vaccine is working for the new variant, if it spreads more, company is on a way to make good money.
And technically we're on a deep.
TP1 - Following EMA100 for a first target
TP2 - 80 is a nice area as a fibonacci level and a resistance.
TP3 - Planinng to hold some till 250, it reached 2 times before, why not a 3rd time?
SL is clear, stop when there is a new low.
MODERNA $305 | Bidding at $220 and $150 Informed Players and speculators at Sub $100 levels are booking gains
we wait for additional drwadowns and re accomodation ACCUMULATION of designated Bankers for the next run up OR cycle
Vaccine COViD was intense HiV was the sell on News..
we await next Drama and Biden Policy on Healthcare etc..
for now Watch or Chrun at key leves (eyeball the box)
this vaccine trade popped in february 2021, can it recover some?all gas no breaks with a full tank and a full trunk. this covid vaccine stock enjoyed a huge runup to the release of the vaccine, but since has languished on the monthly as it lost over 90% of the price high. im not looking towards this as a long term investment, but im buying the rumor that nvax is announcing new trials or a variant innoculation or at least some catalyst and selling the news of that catalyst as well as the release of the vaccine/start of trial. if we stay above pivot, im aiming for upper horizontals and if we fall beneath it im looking for the lower horizontals. im not looking for a huge long on this thing, just maybe some monthly snap back and a move to close gap.
NVAX… once a loser always a loserthe inability of NVAX to properly capitalize on the covid vaccine is a sign of a poorly managed company. was the rise from near penny status exceptional? of course. was the following wealth destruction of epic proportions? sure was.
endless upset longs continue to exit as all good news acts as a selling event. this will be a ride back to single digits for a company who, pre-covid, could not get a single ball across the goal line.
BioNTech showing a solid entryBNTX is finally concluding a year long descending triangle pattern. I see a low risk entry at $150 and will be buying. Stop loss set at $138.49, risking about 8.5%. If we see a large move upward, I could see the stock retesting both its 200 day moving average (likely at $183) and its next major resistance after that at $295. A potential of nearly 100% profit (not to say its a sure bet or smart to dump huge amounts into the trade without the stop loss...). Fundamentally, the company has a P/E of 3, no debt, and a huge free cash flow to fund its mrna platforms for a lot of other diseases partnering with some of the largest pharma companies in the world. Yet another variant of covid, upward pressure from the 50and100 day MAs, large portions of the world unvaccinated, and president biden contracting the virus could be potential catalysts for a move. If you're looking for a bio tech exposure this is a stock that seems to be set up well. Good luck to all.
Novavax - Wassup?Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15.
This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart.
IMHO, it appears to be in technical and fractal alignment.
Weekly chart bounced off a major support two weeks ago, and the last week continued the previous week's bullish end. On the daily chart, Friday's close was the highest daily close in about 5 weeks. with a strong candle closing draws obvious bullish attention.
Target 80, then 125.
Support at 53 and 50.
TNXP Tonix Pharmaceuticals produces the Monkeypox Vaccine ! Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox.
But that`s not all!
They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil.
Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high impact product candidates,”
“By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.”
TNX-2900 received Orphan-Drug designation by the FDA for the treatment of PWS in March 2022.
On this strong pipeline, on 4/18/2022 Noble Financial Initiated Coverage on TNXP with an Outperform rating and a price target of $19.20, while Alliance Global Partners has a price target of $64.
I expect TNXP Tonix Pharmaceuticals to be at least $10 per share.
Looking forward to read your opinion about it.
GOVX Corporate Update soon | 10X Upside Potential Analyst RatingGOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer.
GeoVax Labs will report Q1 2022 financial results on April 27.
Jason McCarthy from Maxim Group has a $10.00 price target for GOVX.
The stock is now $1.01.
Market Cap of only 7.23Mil.
This is a 4X upside potential short term stock in my opinion.
Pfizer RSI bearish divergenceon weekly we can see bearish divergence on RSI. there is also possible h&s forming. we have also fundemantals about rigged vaccine trials for emergency authorization acceptance, vaccine deaths piling up and big shareholders of Pfizer dumping their stock.
sell now!
first profit target 32$
second profit target 1$
covid vaccine maker trying daily higher low (NVAX)novavax blew up after announcing it was making a covid vaccine. they eventually parléd this into a montly uptrend that lasted until september '21. since then it has seen a major decline. the stock is attempting to end that now, or at least find a temporary rally from new multi year lows. this could lead to a short squeeze zipping the price back up towards weekly highs targeting around 94-97
PFIZER (PFE) BUY STRATEGY TA SCENARIO IDEAI made a personal TA on NYSE:PFE using FIB retracements to define when to buy the current pullback reversal.
PFE is currently in a very clear uptrend an its previous pullbacks "reversed" at aroung 50%-61.8% FIB so i think that this current pullback is going to reverse at around 50%.
Before buying:
Check Rsi bounceoff and SMA positionning to form a support
Check if EMA's are likely to cross (strong uptrend)
Dont wait to buy at exactly 50% fib level, price may reverse earlier and you miss the dip/opportunity, or you miss a lower dip at around 61.8%
If price drops further down, may be a sign of a trend reversal !
!! This is not investing advice, you shouldn't (At all) follow my buy setup, this is a personal TA which may differ from yours.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
If you enjoyed this post and agree with me, a like and a sub would be very nice : )
Stay updated for more content
Have a nice Day : ) Bye!
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ARDS 1250% upside potential according to H.C. Wainwright !!!Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment!
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap of only 21.22Mil
52 Week Range 1.49 - 8.47
You can buy the all time low now!
ADGI Potential Neutralizing Activity Against Covid-19 VariantsAdagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2.
Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.
Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.
My price target is the $14.5 resistance.
ARDS Covid-19 Antibody Cocktail | Massive Bullish DivergenceThe chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!
Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap 27.124Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.